SERA — Sera Prognostics Share Price
Last trade - 00:00- $258.11m
- $205.67m
- $0.31m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.4 | ||
| Price to Tang. Book | 3.44 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1,068.24 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -57.55% | ||
| Return on Equity | -43.59% | ||
| Operating Margin | -18247.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.04 | 0.03 | 0.08 | 0.27 | 0.31 | 0.37 | 9.25 | 70.75% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Directors
- Gregory Critchfield CHM
- Jay Moyes CFO (67)
- Robert Harrison CIO
- Jay Boniface CSO
- Nadia Altomare EXO
- Michael Foley OTH
- Sandra Lawrence DRC (64)
- Evguenia Lindgardt DRC
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 1st, 2008
- Public Since
- July 15th, 2021
- No. of Shareholders
- 122
- No. of Employees
- 57
- Sector
- Professional & Commercial Services
- Industry
- Industrials
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 33,091,277
- Address
- 2749 E. Parleys Way, Suite 200, SALT LAKE CITY, 84109
- Web
- https://www.seraprognostics.com/
- Phone
- +1 8015050278
- Auditors
- Ernst & Young LLP
Upcoming Events for SERA
Similar to SERA
biote
NASDAQ Global Market
CompoSecure
NASDAQ Global Market
Kewaunee Scientific
NASDAQ Global Market
MarketWise
NASDAQ Global Market
Onemednet
NASDAQ Global Market
FAQ
As of Today at 17:12 UTC, shares in Sera Prognostics are trading at $6.65. This share price information is delayed by 15 minutes.
Shares in Sera Prognostics last closed at $6.65 and the price had moved by +80.74% over the past 365 days. In terms of relative price strength the Sera Prognostics share price has outperformed the S&P500 Index by +43.82% over the past year.
The overall consensus recommendation for Sera Prognostics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Sera Prognostics does not currently pay a dividend.
Sera Prognostics does not currently pay a dividend.
Sera Prognostics does not currently pay a dividend.
To buy shares in Sera Prognostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.65, shares in Sera Prognostics had a market capitalisation of $220.06m.
Here are the trading details for Sera Prognostics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: SERA
Based on an overall assessment of its quality, value and momentum Sera Prognostics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Sera Prognostics is $2.75. That is 58.65% below the last closing price of $6.65.
Analysts covering Sera Prognostics currently have a consensus Earnings Per Share (EPS) forecast of -$0.99 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sera Prognostics. Over the past six months, its share price has underperformed the S&P500 Index by -11.83%.
As of the last closing price of $6.65, shares in Sera Prognostics were trading +7.99% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sera Prognostics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sera Prognostics' management team is headed by:
- Gregory Critchfield - CHM
- Jay Moyes - CFO
- Robert Harrison - CIO
- Jay Boniface - CSO
- Nadia Altomare - EXO
- Michael Foley - OTH
- Sandra Lawrence - DRC
- Evguenia Lindgardt - DRC